Response of treatment-naive brain metastases to stereotactic radiosurgery.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
received:
25
09
2023
accepted:
15
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
2
5
2024
Statut:
epublish
Résumé
With improvements in survival for patients with metastatic cancer, long-term local control of brain metastases has become an increasingly important clinical priority. While consensus guidelines recommend surgery followed by stereotactic radiosurgery (SRS) for lesions >3 cm, smaller lesions (≤3 cm) treated with SRS alone elicit variable responses. To determine factors influencing this variable response to SRS, we analyzed outcomes of brain metastases ≤3 cm diameter in patients with no prior systemic therapy treated with frame-based single-fraction SRS. Following SRS, 259 out of 1733 (15%) treated lesions demonstrated MRI findings concerning for local treatment failure (LTF), of which 202 /1733 (12%) demonstrated LTF and 54/1733 (3%) had an adverse radiation effect. Multivariate analysis demonstrated tumor size (>1.5 cm) and melanoma histology were associated with higher LTF rates. Our results demonstrate that brain metastases ≤3 cm are not uniformly responsive to SRS and suggest that prospective studies to evaluate the effect of SRS alone or in combination with surgery on brain metastases ≤3 cm matched by tumor size and histology are warranted. These studies will help establish multi-disciplinary treatment guidelines that improve local control while minimizing radiation necrosis during treatment of brain metastasis ≤3 cm.
Identifiants
pubmed: 38697991
doi: 10.1038/s41467-024-47998-8
pii: 10.1038/s41467-024-47998-8
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3728Informations de copyright
© 2024. The Author(s).
Références
Ostrom, Q. T., Wright, C. H. & Barnholtz-Sloan, J. S. Brain metastases: epidemiology. Handb. Clin. Neurol. 149, 27–42 (2018).
doi: 10.1016/B978-0-12-811161-1.00002-5
pubmed: 29307358
Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26–41 (2020).
doi: 10.1038/s41568-019-0205-x
pubmed: 31601988
Kocher, M. et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29, 134–141 (2011).
doi: 10.1200/JCO.2010.30.1655
pubmed: 21041710
Andrews, D. W. et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665–1672 (2004).
doi: 10.1016/S0140-6736(04)16250-8
pubmed: 15158627
Mahajan, A. et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 18, 1040–1048 (2017).
doi: 10.1016/S1470-2045(17)30414-X
pubmed: 28687375
pmcid: 5560102
Vogelbaum, M. A. et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J. Clin. Oncol. 40, 492–516 (2022).
doi: 10.1200/JCO.21.02314
pubmed: 34932393
Chang, E. L. et al. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 53, 272–280 (2003).
doi: 10.1227/01.NEU.0000073546.61154.9A
pubmed: 12925241
Moraes, F. Y. et al. Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose. Neuro Oncol. 21, 242–251 (2019).
doi: 10.1093/neuonc/noy159
pubmed: 30265328
Khan, M. et al. Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases. Front Oncol. 10, 781 (2020).
doi: 10.3389/fonc.2020.00781
pubmed: 32733787
pmcid: 7358601
Linskey, M. E. et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 96, 45–68 (2010).
doi: 10.1007/s11060-009-0073-4
pubmed: 19960227
Schiff, D. et al. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. J. Clin. Oncol. 40, 2271–2276 (2022).
doi: 10.1200/JCO.22.00333
pubmed: 35561283
Gondi, V. et al. Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pr. Radiat. Oncol. 12, 265–282 (2022).
doi: 10.1016/j.prro.2022.02.003
Lehrer, E. J. et al. Single versus Multifraction Stereotactic Radiosurgery for Large Brain Metastases: An International Meta-analysis of 24 Trials. Int J. Radiat. Oncol. Biol. Phys. 103, 618–630 (2019).
doi: 10.1016/j.ijrobp.2018.10.038
pubmed: 30395902
Minniti, G. et al. Single-Fraction Versus Multifraction (3 x 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. Int J. Radiat. Oncol. Biol. Phys. 95, 1142–1148 (2016).
doi: 10.1016/j.ijrobp.2016.03.013
pubmed: 27209508
Soliman, H., Das, S., Larson, D. A. & Sahgal, A. Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget 7, 12318–12330 (2016).
doi: 10.18632/oncotarget.7131
pubmed: 26848525
pmcid: 4914287
Li, S. et al. A unified multi-activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS). Med. Phys. 48, 2038–2049 (2021).
doi: 10.1002/mp.14690
pubmed: 33590493
Brown, P. D. et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 18, 1049–1060 (2017).
doi: 10.1016/S1470-2045(17)30441-2
pubmed: 28687377
pmcid: 5568757
Kjellberg, R. N., Masamitsu, A. Stereotactic Bragg peak proton radiosurgery results. In Modern Stereotactic Neurosurgery, (ed. Lunsford, L. D.) 463–470 (Martinus Nijhoff, 1988).
Crouzen, J. A. et al. SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases. BMC Cancer 23, 273 (2023).
doi: 10.1186/s12885-023-10761-1
pubmed: 36964529
pmcid: 10039548
Sankey, E. W. et al. Operative and peri-operative considerations in the management of brain metastasis. Cancer Med. 8, 6809–6831 (2019).
doi: 10.1002/cam4.2577
pubmed: 31568689
pmcid: 6853809
Wernicke, A. G. et al. Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. J. Neurosurg. 121, 338–348 (2014).
doi: 10.3171/2014.3.JNS131140
pubmed: 24785322
pmcid: 4249933
Yeboa, D. N. et al. MD Anderson Phase III Randomized Preoperative Stereotactic Radiosurgery (SRS) vs. Postoperative SRS for Brain Metastases Trial. Int. J. Radiat. Oncol.*Biol.*Phys. 117, e160–e161 (2023).
doi: 10.1016/j.ijrobp.2023.06.990
Beg, U. et al. Current Landscape and Future Prospects of Radiation Sensitizers for Malignant Brain Tumors: A Systematic Review. World Neurosurg. 151, e839–e856 (2021).
doi: 10.1016/j.wneu.2021.04.134
pubmed: 33974987
Baschnagel, A. M. et al. ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. Mol. Cancer Ther. 20, 2129–2139 (2021).
doi: 10.1158/1535-7163.MCT-21-0305
pubmed: 34413128
pmcid: 8571002
Ene, C. I. et al. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Neuro Oncol. 22, 639–651 (2020).
doi: 10.1093/neuonc/noz226
pubmed: 31793634
Ko, E. C. & Formenti, S. C. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J. Radiat. Biol. 95, 936–939 (2019).
doi: 10.1080/09553002.2019.1623429
pubmed: 31120369
Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med 24, 1845–1851 (2018).
doi: 10.1038/s41591-018-0232-2
pubmed: 30397353
pmcid: 6286242
Takahashi, J. & Nagasawa, S. Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review. Int. J. Mol. Sci. 21 https://doi.org/10.3390/ijms21239324 (2020).
Singh, C., Qian, J. M., Yu, J. B. & Chiang, V. L. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases. J. Neurosurg. 132, 512–517 (2019).
doi: 10.3171/2018.10.JNS181371
pubmed: 30771783
Kim, P. H. et al. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. Eur. Radio. 31, 4114–4129 (2021).
doi: 10.1007/s00330-020-07514-0
Fang, P. et al. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J. Neurooncol 133, 595–602 (2017).
doi: 10.1007/s11060-017-2470-4
pubmed: 28500560
Salari, E., Elsamaloty, H., Ray, A., Hadziahmetovic, M. & Parsai, E. I. Differentiating Radiation Necrosis and Metastatic Progression in Brain Tumors Using Radiomics and Machine Learning. Am. J. Clin. Oncol. 46, 486–495 (2023).
doi: 10.1097/COC.0000000000001036
pubmed: 37580873
pmcid: 10589425
Nichelli, L. & Casagranda, S. Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis. Curr. Opin. Oncol. 33, 597–607 (2021).
doi: 10.1097/CCO.0000000000000793
pubmed: 34534142
pmcid: 8528135
Ahluwalia, M. et al. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. J. Neurosurg. 130, 804–811 (2018).
doi: 10.3171/2017.11.JNS171273
pubmed: 29726782
Kohutek, Z. A. et al. Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J. Neurooncol 125, 149–156 (2015).
doi: 10.1007/s11060-015-1881-3
pubmed: 26307446
pmcid: 4726630
Minniti, G. et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat. Oncol. 6, 48 (2011).
doi: 10.1186/1748-717X-6-48
pubmed: 21575163
pmcid: 3108308
Sneed, P. K. et al. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J. Neurosurg. 123, 373–386 (2015).
doi: 10.3171/2014.10.JNS141610
pubmed: 25978710
Barbour, A. B. et al. Radiation Therapy Practice Patterns for Brain Metastases in the United States in the Stereotactic Radiosurgery Era. Adv. Radiat. Oncol. 5, 43–52 (2020).
doi: 10.1016/j.adro.2019.07.012
pubmed: 32051889
Chang, E. L. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10, 1037–1044 (2009).
doi: 10.1016/S1470-2045(09)70263-3
pubmed: 19801201
Kaplan, E. L. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457–481 (1958).
doi: 10.1080/01621459.1958.10501452
RCoreTeam. A language and environment for statistical computing (R Foundation for Statistical Computing, 2022).
Therneau, T. M. A Package for Survival Analysis in R. R package version 3.4-0. https://CRAN.R-project.org/package=survival (2022).
Terry, M., Therneau, P. M. G. Modeling Survival Data: Extending the Cox Model (Springer, 2000).
Lenth, R. V. emmeans: Estimated Marginal Means, aka Least-Squares Means. R package version 1.8.4-1. https://CRAN.R-project.org/package=emmeans . (2023).